🇺🇸 FDA
Patent

US 11987821

Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy

granted A61KA61K35/12A61K38/45

Quick answer

US patent 11987821 (Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy) held by Entrada Therapeutics, Inc. expires Mon May 16 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Entrada Therapeutics, Inc.
Grant date
Tue May 21 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 16 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K35/12, A61K38/45, A61K47/60, A61K47/645